

Drug Utilization Review Board

Meeting Minutes

Thursday, February 9, 2023

7:15 a.m. to 8:30 a.m.

Google Meet

Board Members Present:

Eric Cannon, PharmD, FAMCP, Board
Chair

Colby Hancock, PharmD

Jennifer Brinton, MD

Judith Turner, DVM, PharmD

Katherine Smith, PharmD

Michelle Hofmann, MD

Neal Catalano, PharmD

Sharon Weinstein, MD

Susan Siegfried, MD

Board Members Excused:

Kumar Shah, MSc, PEng

Dept. of Health/Div. of Health Care Financing Staff Present:

Lisa Angelos, PharmD, Pharmacy
Director

Andrea Rico, CPhT, CPC

Bryan Larson, PharmD

Craig Hummel, MD

James Stamos, Office Director

Joe Busby, RPh, MBA

Jennifer Strohecker, PharmD,
Medicaid Director

Luis Moreno, PharmD

Ngan Huynh, PharmD

Stephanie Byrne, PharmD

Utah Medicaid Presenter:

Ngan Huynh, PharmD

Other Individuals Present:

Amy Hale, PharmD Janssen

Daniel Cornett, ImmunoGen

Evan Rushing, Alkermes

Heidi Goodrich, Molina Healthcare

Jason Bott, Eli Lilly

Kelly Wright, ImmunoGen

Kenneth Berry, Alkermes

Kevin Gallager

Madeline Shurtliff, Otsuka

Matt Call, UUHP

Matt Metcalf, CSL Vifor

Michael Zarob, Merck

Monet Luloh, PharmD U of U DRRC

Natalie Rose, Gilead Sciences

San Tran, Genentech

Stephen Hiatt, APRN UT Navajo Health

Tyler Lister, PharmD U of U

Windi Woods, DNP Odyssey House

Drug Utilization Review Board

Meeting Minutes

Meeting conducted by: Eric Cannon

1. **Welcome:** Ngan Huynh opened the meeting and reminded everyone who attended the meeting to identify themselves via meeting chat or by sending an email to medicaidpharmacy@utah.gov. Eric Cannon announced a quorum.
2. **Housekeeping:** Ngan Huynh expressed gratitude for Kyle Turner's service with the DUR Board and announced Colby Hancock as a new board member.

Jen Strohecker shared pharmacy-related updates regarding:

- Continuous enrollment unwinding begins 4/1/2023
- Unwinding dashboard resources
- PHE ends 5/11/2023
- S.B. 16 Transgender Medical Treatments and Procedures Amendments (2023) which has an 1/28/2023 effective date and creates policy for hormonal treatment for minors
- Currently actively recruiting for a full-time Medical Director who will report to Dr. Strohecker

3. **Review and Approval of December Minutes:** Neal Catalano, PharmD motioned to approve the minutes from December. Sharon Weinstein, MD seconded the motion. Unanimous approval.

4. **Lybalvi (olanzapine/samidorphan):**

a. **Information:**

1. Ngan Huynh presented findings on Lybalvi.

b. **Public Comment:**

1. Kenneth Berry, MSL Alkermes presented on Lybalvi
2. Windi Woods, Odyssey House shared patient experience
3. Stephen Hiatt, APRN-Psych Utah Navajo Health System

5. **Lybalvi (olanzapine/samidorphan) Prior Authorization:**

- a. **Information:** Ngan Huynh shared the proposed prior authorization criteria for Lybalvi (olanzapine/samidorphan).

Drug Utilization Review Board

Meeting Minutes

Criteria for Approval: (*ALL of the following must be met with chart notes submitted for all requests*)

- ☐ Patient is 18 years of age or older
- ☐ Diagnosis of one of the following:
 - ☐ Schizophrenia
 - ☐ Bipolar I disorder
- ☐ Meet ONE of the following criteria:
 - ☐ Patient has positive clinical response to olanzapine **AND** gained more than 10 % of baseline body weight prior to start olanzapine **OR**
 - ☐ Trial and failure of at least two preferred atypical antipsychotic medications. One of them MUST be aripiprazole **OR** lurasidone:
 - Medication(s) Name: _____ Chart Note Page #: _____
 - Medication(s) Name: _____ Chart Note Page #: _____
- ☐ Baseline body weight prior to starting Lybalvi: _____
- ☐ Patient is not concurrently using Lybalvi with opioid agonists. Patient must be off short-acting opioid agonists for at least 7 days, and long-acting opioid agonists for 14 days.

Re-authorization Criteria: (*ALL of the following must be met with chart notes submitted for all requests*)

- ☐ Updated notes that support the continued clinical benefit of the medication must be submitted.
- ☐ The patient's increase in body weight is **NOT** more than 10% baseline body weight prior to start Lybalvi.
 - ☐ Updated body weight after starting Lybalvi: _____

Initial Authorization: Up to three (3) months

Re-authorization: Up to one (1) year

b. Board Discussion:

Dr. Weinstein shared her thoughts on opioid use concurrently with Lybalvi on the PA document and asking for others' thoughts on buprenorphine use and making the distinction on the prior authorization form between agonists by adding "opioid agonist".

Further clarification on time frames for patients who were taking short-acting and long-acting opioids, as this is a contraindication. Dr. Weinstein does not feel the time frames are medically necessary on the PA form.

Dr. Siegfried mentioned H.B. 437 which refers to the preferred drug list and if this prior authorization can be enforced.

Bryan Larson clarified further on the H.B. 437 comment and shared that Medicaid Pharmacy does have oversight to create prior authorization for psychotropic medications.

Dr. Weinstein mentioned that we are lacking data on patients who have eating disorders and substance use disorders which are more common in the Medicaid population.

c. Board Action:

Sharon Weinstein, MD moved to approve on amended PA and

Drug Utilization Review Board

Meeting Minutes

Katherine Smith, PharmD seconded the motion. PA is moved as amended.

6. Meeting Chat Transcript:

00:19:14.888,00:19:17.888

Sharon M Weinstein MD: thank you, appreciate the update!

00:19:26.589,00:19:29.589

Jennifer Strohecker (DHHS): Medicaid unwinding materials/resources:
<https://medicaid.utah.gov/unwinding/>

00:19:59.964,00:20:02.964

Jennifer Strohecker (DHHS): SB16-
<https://le.utah.gov/~2023/bills/static/SB0016.html>

00:20:46.762,00:20:49.762

Jennifer Strohecker (DHHS): Utah Code 58-1-603

00:40:51.144,00:40:54.144

Eric Cannon: thanks everyone - I apologize for dropping early - thank you Ngan

00:41:54.959,00:41:57.959

Lisa Angelos (DHHS): For our non-committee guests: please enter your affiliation information here in the chat or via e-mail to medicaidpharmacy.utah.gov

00:49:30.157,00:49:33.157

Stephen Hiatt: Stephen Hiatt, APRN

00:49:58.494,00:50:01.494

Stephen Hiatt: Utah Navajo Health System

00:54:01.027,00:54:04.027

Lisa Angelos (DHHS): Thanks, Stephen.

Drug Utilization Review Board

Meeting Minutes

00:54:41.370,00:54:44.370

Amy Hale: Amy Hale, PharmD, Janssen Scientific Affairs

7. **The next meeting scheduled for Thursday, March 09, 2023 will address Adult Pulmonary Hypertension**
8. **Public Meeting Adjourned:** Neal Catalano, PharmD motioned to adjourn the meeting. Katherine Smith, PharmD seconded the motion. Unanimous approval.

Audio recordings of DUR meetings are available online at:

<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>